Core Viewpoint - Three new stocks from the Sci-Tech Innovation Board are set to be issued, with a total expected fundraising of 9.751 billion yuan [1][2]. Group 1: Company Summaries - **He Yuan Bio**: - Issuance date: October 14, 2025 - Total shares to be issued: 89.4514 million - Online issuance: 14.3120 million shares - Issuance price: 29.06 yuan - Company specializes in innovative biopharmaceuticals with a leading global plant bioreactor technology platform [1]. - Projected net profit for 2023 and 2024: -187 million yuan and -151 million yuan, respectively, with year-on-year changes of -30.22% and 19.04% [1]. - **Xi'an Yicai**: - Issuance date: October 16, 2025 - Total shares to be issued: 538 million - Online issuance: 53.78 million shares - The company focuses on the research, production, and sales of 12-inch silicon wafers in the semiconductor silicon materials sector [2]. - Projected net profit for 2023 and 2024: -578 million yuan and -738 million yuan, respectively, with year-on-year changes of -40.35% and -27.63% [2]. - **Bibet**: - Issuance date: October 17, 2025 - Total shares to be issued: 90 million - Online issuance: 14.4 million shares - The company is a biopharmaceutical firm focused on innovative drug development for major diseases such as cancer and autoimmune diseases [2]. - Projected net profit for 2023 and 2024: -173 million yuan and -55.9983 million yuan, respectively, with year-on-year changes of 8.27% and 67.59% [2].

武汉禾元生物科技股份有限公司 保荐机构（联席主承销商）：国泰海通证券股份有限公司 发行情况： | 殿票代码 | 688765 | 股票简称 | 禾元生物 | | --- | --- | --- | --- | | 申购代码 | 787765 | 上市地点 | 上海证券交易所科创板 | | 发行价格(元/股) | 29.06 | 发行市盈率 | | | 市盈率参考行业 | 医药制造业 | 参考行业市盈率(最新) | 32.08 | | 发行面值(元) | 1 | 实际募集资金总额(亿 元) | 66.99 | | 网上发行日期 | 2025-10-14 (周二) | 网下載雪目期 | 2025-10-14 | | 网上发行数量(股) | 14.312.000 | 网下配雪数量(股) | 57.658.846 | | 老股转让数量(股) | | 总发行数量(股) | 89.451.354 | | 申购数量上限(股) | 14.000 | 中签到款日期 | 2025-10-16 (周四) | | 网上顶格申购需配市值 (万元) | 14.00 | 网上申购市值确认日 | T-2 日(T:网上申购日) | | 网下申 ...

来源：市场资讯 （来源：国金证券第5小时） | 申购价格 | 所属行业 | 发行后市净率 | 行业最近一个月平 | | --- | --- | --- | --- | | | | | 均静态市盈率 | | 29.06元 | 医药制造业 | 3.43倍 | 32.08倍 | | | | 未盈利 | | | 可比公司 | | | | --- | --- | --- | | 市净率(倍) 证券简称 | 市值(亿元) | 近一月涨跌 | | 神州细胞 | 178.20 | 243.11 | -9.02% | | --- | --- | --- | --- | | 百奥泰 | 16.50 | 114.37 | -11.87% | 学势 公司主营业务介绍 公司是一家创新型生物医药企业,拥有全球领先的植物生物反 应器技术平台。公司核心产品HY1001已完成国内III期临床研 究,研究结果显示其已达到主要和次要临床研究终点,展现出 良好的安全性。 | | | 主要财务数据 | | | --- | --- | --- | --- | | | 2022年 | 2023年 | 2024年 | | 营业收入 单位:亿元 | 0.13 ...

Group 1: Earnings Forecasts - Chuangjiang New Material expects a net profit of 350 million to 380 million yuan for the first three quarters of 2025, representing a year-on-year increase of 2057.62% to 2242.56% [2] - Chenguang Biological anticipates a net profit of 278 million to 314 million yuan for the first three quarters of 2025, reflecting a year-on-year growth of 344.05% to 401.55% [2] - Sanmei Co. forecasts a net profit of 1.524 billion to 1.646 billion yuan for the first three quarters of 2025, indicating a year-on-year increase of 171.73% to 193.46% [3] - Juchip Technology expects a revenue of 721 million yuan for the first three quarters of 2025, a year-on-year increase of 54.50% [3] - Feirongda anticipates a net profit of 275 million to 300 million yuan for the first three quarters of 2025, representing a year-on-year growth of 110.80% to 129.96% [4] Group 2: Share Buybacks - Jiuan Medical plans to repurchase shares with a total amount between 300 million and 600 million yuan, with a maximum repurchase price of 53.5 yuan per share [5] - COSCO Shipping Holdings intends to repurchase between 50 million and 100 million shares, with an estimated repurchase amount of 749 million to 1.498 billion yuan [5] - Zhonggong International plans to repurchase shares with a total amount not exceeding 100 million yuan, with a maximum repurchase price of 12.85 yuan per share [5] - Fujilai intends to repurchase shares with a total amount between 20 million and 40 million yuan, with a maximum repurchase price of 40 yuan per share [6] Group 3: Significant Shareholding Changes - Shanghai Pudong Development Bank received notification that China Mobile increased its shareholding in the bank to 18.18% after converting 563.1 million yuan of convertible bonds into 450 million shares [7] Group 4: Other Earnings Forecasts - Yuegui Co. expects a net profit of 420 million to 470 million yuan for the first three quarters of 2025, reflecting a year-on-year increase of 86.87% to 109.11% [9] - Zhongshi Technology anticipates a net profit of 230 million to 270 million yuan for the first three quarters of 2025, indicating a year-on-year growth of 74.16% to 104.45% [9] - Longxin General expects a net profit of 1.52 billion to 1.62 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 69.13% to 80.26% [10] - Dongfang Iron Tower forecasts a net profit of 750 million to 900 million yuan for the first three quarters of 2025, reflecting a year-on-year growth of 60.83% to 93% [10]

每经AI快讯，多瑞医药（SZ 301075，收盘价：40.08元）10月13日晚间发布公告称，经公司向深圳证券 交易所申请，公司股票自2025年10月14日（星期二）上午开市起复牌。 截至发稿，多瑞医药市值为32亿元。 每经头条（nbdtoutiao）——中科院博导带队，中国固态电池技术又有重大突破！ （记者 曾健辉） 2024年1至12月份，多瑞医药的营业收入构成为：医药制造业占比57.85%，其他占比42.15%。 ...

截至发稿，圣诺生物市值为65亿元。 每经AI快讯，圣诺生物（SH 688117，收盘价：41.58元）10月13日晚间发布业绩预告，成都圣诺生物科 技股份有限公司预计2025年前三季度实现归属于母公司所有者的净利润约1.14亿元~1.4亿元，与上年同 期相比，增加5724.99万元~8262.7万元，同比增加100.53%~145.1%。业绩变动主要原因是，报告期内， 公司主营业务稳定发展，随着投建产能不断落地，公司多肽原料药业务订单需求持续增长，带动公司整 体业绩稳步提升，与同期相比业绩实现较大增长，使得公司保持较强的市场竞争力与持续盈利能力。 2024年1至12月份，圣诺生物的营业收入构成为：医药制造业占比98.91%，其他业务占比1.09%。 （记者 胡玲） 每经头条（nbdtoutiao）——AI技术滥用调查：明星可被"一键换装"，"擦边"内容成流量密码，技术防 线为何形同虚设？ ...

证券研究报告 2025 年 10 月 13 日 星期一 【新股发行跟踪（20251013）】 一、上周新股表现情况 上周（10 月 6 日-10 月 10 日）共有 1 只新股上市，上市首日涨跌幅为 349.82%。 表 1：上周新股表现 新股发行跟踪 图 2：周度新股上市首日涨跌幅均值及破发率 | 股票代码 | 股票简称 | 上市日期 | 上市 | 发行价 | 发行市 | 证监会行业 | 首日收盘 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 板块 | 格（元） | 盈率 | | 涨跌幅(%) | | 920080.BJ | 奥美森 | 2025-10-10 | 北证 | 8.25 | 12.52 | 专用设备制造业 | 349.82 | 资料来源：东莞证券研究所，iFinD 二、周度新股上市情况走势 从周度新股上市规模来看，上周（10 月 6 日-10 月 10 日，下同）较上 上周（9 月 29 日-10 月 3 日，下同）相比，上市新股数量少 1 只，首发募 资金额少 21.79 亿元。 从周度上市新股表现来看，上周与上上周均无 ...

固定收益 | 动态跟踪 保持短久期、高流动性策略 信用债市场周观察 研究结论 风险提示 政策变化超预期；货币政策变化超预期；经济基本面变化超预期；信用风险暴露超预 期；数据统计可能存在遗误 报告发布日期 2025 年 10 月 13 日 | 齐晟 | 执业证书编号：S0860521120001 | | --- | --- | | | qisheng@orientsec.com.cn | | | 010-66210535 | | 杜林 | 执业证书编号：S0860522080004 | | | dulin@orientsec.com.cn | | | 010-66210535 | | 王静颖 | 执业证书编号：S0860523080003 | | | wangjingying@orientsec.com.cn | | | 021-63326320 | | 徐沛翔 | 执业证书编号：S0860525070003 | | | xupeixiang@orientsec.com.cn | | | 021-63326320 | | 估值小幅修复，底仓品种价值显现：可转 | 2025-09-29 | | --- | --- ...

Summary of New Stock Offerings from October 13 to October 17 Core Viewpoint A total of five new stocks will be available for subscription in the upcoming week, covering industries such as home furnishings, pharmaceutical manufacturing, and computer communication equipment. Notable companies include Marco Polo, a leader in the domestic ceramic tile industry, and Heyuan Bio, a pioneer in the large-scale production of pharmaceutical proteins using rice embryo cell bioreactors. Group 1: Marco Polo - Marco Polo is the leading company in the domestic ceramic tile industry, with its "Marco Polo Tile" brand value ranking first in the industry for over a decade [2] - The company has a total market value of 14.79 billion, with an issuance price-to-earnings ratio of 14.27, significantly lower than the industry average of 32.2 [2] Group 2: Heyuan Bio - Heyuan Bio is recognized as the first in China to utilize rice embryo cell bioreactors for the large-scale production of pharmaceutical proteins, referred to as "rice hematopoiesis" [3] - The company is set to have its human albumin injection HY1001 approved by July 2025 [3] Group 3: Super Electronics - Super Electronics is a major global supplier of automotive electronic PCBs, covering the demand for PCBs across various parts of vehicles [4] - The company operates in the computer, communication, and other electronic equipment manufacturing sector [4] Group 4: Xi'an Yicai - Xi'an Yicai has developed into the largest producer and seller of 12-inch silicon wafers in mainland China, ranking sixth globally [4] - The company operates in the computer, communication, and other electronic equipment manufacturing sector [4] Group 5: Bibet - Bibet focuses on the independent research and development of innovative drugs, targeting major diseases such as tumors, autoimmune diseases, and metabolic diseases [4] - The company operates in the pharmaceutical manufacturing industry [4]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002737 证券简称：葵花药业 公告编号：2025-059 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 一、董事会会议召开情况 葵花药业集团股份有限公司（以下简称"公司"或"本公司"）第五届董事会第十一次会议于2025年10月10 日上午9时30分以通讯方式召开。会议由公司董事长关玉秀女士召集，会议通知及议案于2025年9月26日 通过电子邮件形式发出。会议应参加表决董事9人，实际参加表决董事9人。 本次会议召集、召开程序符合《公司法》及相关法律法规以及《公司章程》之规定，会议决议合法有 效。 二、董事会会议审议情况 1、审议通过《关于授权葵花集团及其下属企业使用公司部分注册商标暨关联交易的议案》 《关于授权控股股东及下属企业使用公司部分注册商标暨关联交易的公告》披露于本公司指定信息披露 媒体《证券日报》、《上海证券报》、巨潮资讯网（http://www.cninfo.com.cn）。 同意授权控股股东葵花集团有限公司（含其合并报表范围内子公司）使用公司第45649037号"葵花"文字 商标（核 ...